Ginkgo Bioworks is involved in synthetic biology, providing data-driven R&D services for various industries including agriculture and biopharma. Self-described as the Organism Company.

Ginkgo Bioworks

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

T. Rowe Price

Viking Global Investors

Cascade Investment

Illumina

Ginkgo Bioworks, Inc.

This week on Foundry Theory! What is it about biotech R&D that makes collaboration challenging? How can we make it easier?
https://hubs.la/Q02NTygX0

We're excited to welcome Patrick Boyle as an Advisor at SIC. Patrick is currently Ginkgo Bioworks, Inc.'s Chief Scientific Officer, having been at Ginkgo from the earliest days as one of the first full time scientist hires at the company in 2012. As a pioneer in synthetic and computational biology, Patrick brings unparalleled expertise to our extended network. His experience in developing Ginkgo’s codebase and driving customer-focused business development is a powerful addition to our firm’s toolkit. Welcome Patrick!

https://lnkd.in/eZjsX4ZQ

I tried to go a bit sassy and provocative in this week's video, asking "which type of nerds are the coolest?"

My professional opinion: it's the bio nerds

We're #hiring a new Director, Infrastructure Enablement in United States. Apply today or share this post with your network.

Ginkgo is pleased to announce Max Breet, Director of Business Development EMEA, will be joined by other industry experts at this year's upcoming GLOBSEC Forum to discuss the growing need for robust biosecurity infrastructure and what it will take to get us there!

#GLOBSEC2024 #GLOBSECPRAGUE

Allozymes is a competitor of Ginkgo Bioworks in the biotechnology industry, focusing on cell programming and providing similar services.

Allozymes

Algal Bio is a competitor of Ginkgo Bioworks in the biotechnology sector, specializing in cell programming and offering comparable services.

Algal Bio

EnginZyme is a direct competitor of Ginkgo Bioworks, providing cell programming services and solutions across diverse markets.

EnginZyme

Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, specializing in using genetic engineering to produce bacteria with industrial applications for other biotech companies. The company aims to leverage biology as an advanced manufacturing technology to program cells for various applications in therapeutics, agriculture, nutrition, wellness, and more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Oct 2, 2024 10:49 AM	2f42de83
public peers	general	Oct 2, 2024 10:49 AM	a8c1086d
news daily refresh	general	Oct 2, 2024 10:49 AM	2e34b95c
news processing daily refresh	general	Oct 2, 2024 10:49 AM	32766900
news impact assignment daily	general	Oct 2, 2024 10:49 AM	1eab5c18
news processing basic	general	Oct 2, 2024 10:49 AM	dbf61eaf
company summary	general	Oct 2, 2024 10:49 AM	a8dc7527
signals	general	Oct 2, 2024 10:49 AM	e0e4b8b9
crunchbase trigger	general
crunchbase profile	general
li profile	general	Oct 2, 2024 10:49 AM	8c37d04d
translate crunchbase fundingrounds	general
peers	general	Oct 2, 2024 10:49 AM	ba7006b7
news basic	general	Oct 2, 2024 10:49 AM	e8657e37
bundesanzeiger	filings	Oct 2, 2024 10:49 AM	06b238d5
merger acquisitions	company_analysis	Oct 2, 2024 10:49 AM	1e5a1092
financials download nd	financials
private financials	financials

COM:GINKGOBIOWORKS

Ginkgo Bioworks

Last Close

6.36

21/11 18:19

Market Cap

725.64M

Beta: -

Volume Today

496.03K

Avg: -